Another Study Raps Ph.D. Overproduction

Shirley M. Tilghman At a meeting right after Labor Day, Princeton University's molecular biology department surveyed the plans of its recently graduated seniors, and professor Shirley M. Tilghman wasn't happy with the results. Thirty-one out of 72 students awarded bachelor's degrees last June were going to medical school, eight planned to do community-service work--and only three were heading directly for Ph.D. or M.D.-Ph.D. programs. Recalling the meeting, Tilghman notes that the cohort of do

Written byDouglas Steinberg
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share


Shirley M. Tilghman
At a meeting right after Labor Day, Princeton University's molecular biology department surveyed the plans of its recently graduated seniors, and professor Shirley M. Tilghman wasn't happy with the results. Thirty-one out of 72 students awarded bachelor's degrees last June were going to medical school, eight planned to do community-service work--and only three were heading directly for Ph.D. or M.D.-Ph.D. programs.

Recalling the meeting, Tilghman notes that the cohort of doctoral wanna-bes has never topped 10 percent of graduates. But she describes this year's yield as the worst ever. "It worries me because the future of science needs these kids opting to do science," she says. "And they're not opting to."

A new 120-page report from the National Research Council (NRC) helps explain why. "Addressing the Nation's Changing Needs for Biomedical and Behavioral Scientists" (www.nap.edu/books/0309069815/html) is the 11th in a series of reports since 1975 mandated by ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies